Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 69
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Neuroendocrinol ; 25(2): 206-15, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22963497

RESUMO

Normal anterior pituitary function is essential for fertility. Release from the gland of the reproductive hormones luteinising hormone and follicle-stimulating hormone is regulated primarily by hypothalamically-derived gonadotrophin-releasing hormone (GnRH), although other releasing factors (RF) have been postulated to exist. Using a bioinformatic approach, we have identified a novel peptide, phoenixin, that regulates pituitary gonadotrophin secretion by modulating the expression of the GnRH receptor, an action with physiologically relevant consequences. Compromise of phoenixin in vivo using small interfering RNA resulted in the delayed appearance of oestrus and a reduction in GnRH receptor expression in the pituitary. Phoenixin may represent a new class of hypothalamically-derived pituitary priming factors that sensitise the pituitary to the action of other RFs, rather than directly stimulating the fusion of secretary vesicles to pituitary membranes.


Assuntos
Hormônios Hipotalâmicos/metabolismo , Hormônios Peptídicos/metabolismo , Hormônios Hipofisários/isolamento & purificação , Reprodução/genética , Sequência de Aminoácidos , Animais , Células Cultivadas , Clonagem Molecular , Relação Dose-Resposta a Droga , Feminino , Fármacos para a Fertilidade/química , Fármacos para a Fertilidade/isolamento & purificação , Fármacos para a Fertilidade/metabolismo , Fármacos para a Fertilidade/farmacologia , Hormônio Liberador de Gonadotropina/genética , Hormônio Liberador de Gonadotropina/metabolismo , Hormônios Hipotalâmicos/genética , Hormônios Hipotalâmicos/isolamento & purificação , Hormônios Hipotalâmicos/farmacologia , Hormônio Luteinizante/sangue , Masculino , Dados de Sequência Molecular , Hormônios Peptídicos/genética , Hormônios Peptídicos/isolamento & purificação , Hormônios Peptídicos/farmacologia , Hormônios Hipofisários/genética , Hormônios Hipofisários/metabolismo , Hormônios Hipofisários/farmacologia , Ratos , Ratos Sprague-Dawley , Reprodução/efeitos dos fármacos , Reprodução/fisiologia , Homologia de Sequência de Aminoácidos
2.
J Neuroendocrinol ; 16(10): 842-9, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15500544

RESUMO

Neuropeptide B (NPB) was identified to be an endogenous, peptide ligand for the orphan receptors GPR7 and GPR8. Because GPR7 is expressed in rat brain and, in particular, in the hypothalamus, we hypothesized that NPB might interact with neuroendocrine systems that control hormone release from the anterior pituitary gland. No significant effects of NPB were observed on the in vitro releases of prolactin, adrenocorticotropic hormone (ACTH) or growth hormone (GH) when log molar concentrations ranging from 1 pM to 100 nM NPB were incubated with dispersed anterior pituitary cells harvested from male rats. In addition NPB (100 nM) did not alter the concentration response stimulation of prolactin secretion by thyrotropin-releasing hormone, ACTH secretion by corticotropin-releasing factor (CRF) and GH secretion by GH-releasing hormone. However, NPB, when injected into the lateral cerebroventricle (i.c.v.) of conscious, unrestrained male rats, elevated prolactin and corticosterone, and lowered GH levels in circulation. The threshold dose for the effect on corticosterone and prolactin levels was 1.0 nmol, while that for the effect on GH release was 3.0 nmol NPB. Pretreatment with a polyclonal anti-CRF antiserum completely blocked the ability of NPB to stimulate ACTH release and significantly inhibited the effect of NPB on plasma corticosterone levels. NPB administration i.c.v. did not significantly alter plasma vasopressin and oxytocin levels in conscious rats. It did stimulate feeding (minimum effective dose 1.0 nmol) in sated animals in a manner similar to that of the other endogenous ligand for GPR7, neuropeptide W. We conclude that NPB can act in the brain to modulate neuroendocrine signals accessing the anterior pituitary gland, but does not itself act as a releasing or inhibiting factor in the gland, at least with regard to prolactin, ACTH and GH secretion.


Assuntos
Ingestão de Alimentos/efeitos dos fármacos , Hormônios/metabolismo , Neuropeptídeos/farmacologia , Estresse Psicológico/metabolismo , Hormônio Adrenocorticotrópico/metabolismo , Animais , Células Cultivadas , Relação Dose-Resposta a Droga , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Injeções Intraventriculares , Masculino , Neuropeptídeos/administração & dosagem , Testes de Neutralização , Ocitocina/metabolismo , Adeno-Hipófise/citologia , Adeno-Hipófise/metabolismo , Prolactina/metabolismo , Radioimunoensaio , Ratos , Ratos Sprague-Dawley , Estimulação Química , Vasopressinas/metabolismo
3.
Am J Physiol Regul Integr Comp Physiol ; 281(4): R1140-5, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11557621

RESUMO

The hypocretin/orexins (Hcrts/ORXs) are peptides produced in neurons in the lateral hypothalamic area that project to neuroendocrine centers in the hypothalamus. Hcrt/ORX receptors are present in the hypothalamus and anterior pituitary gland. We examined the possibility that the Hcrts/ORXs, which we have demonstrated previously to act in the brain to stimulate sympathetic function, could alter stress hormone secretion by a direct pituitary action. In vitro studies revealed a dose-related inhibitory effect of the Hcrts/ORXs on corticotropin-releasing hormone-stimulated ACTH secretion that appeared to be mediated via the orexin-1 receptor and to be expressed at doses (threshold dose 1 nM orexin A) similar to the affinity constant for the receptor. The effect was not due to abrogation of the cAMP response of the corticotroph to corticotropin-releasing hormone and was not pertussis toxin sensitive, suggesting a non-G(i)-mediated mechanism. Instead, a G(q)-mediated signaling mechanism was indicated by the ability of protein kinase C blockade with calphostin C to reverse the inhibitory action of orexin A. Orexin A and orexin B did not significantly alter basal ACTH secretion in vitro and did not alter basal or releasing factor-stimulated secretion of luteinizing hormone, prolactin, thyroid-stimulating hormone or growth hormone from cells harvested from male or random-cycle female donors. Our data suggest a direct, pituitary action of the Hcrts/ORXs to modulate the endocrine response to stress and identify the potential cellular mechanism of a unique biological action of the peptides in the anterior pituitary gland.


Assuntos
Proteínas de Transporte/farmacologia , Peptídeos e Proteínas de Sinalização Intracelular , Neurônios/efeitos dos fármacos , Neuropeptídeos/farmacologia , Adeno-Hipófise/efeitos dos fármacos , Hormônio Adrenocorticotrópico/metabolismo , Animais , Células Cultivadas , Hormônio Liberador da Corticotropina/farmacologia , AMP Cíclico/metabolismo , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/farmacologia , Feminino , Subunidades alfa Gq-G11 de Proteínas de Ligação ao GTP , Proteínas Heterotriméricas de Ligação ao GTP/metabolismo , Masculino , Neurônios/metabolismo , Receptores de Orexina , Orexinas , Toxina Pertussis , Adeno-Hipófise/citologia , Adeno-Hipófise/metabolismo , Hormônios Hipofisários/metabolismo , Proteína Quinase C/antagonistas & inibidores , Ratos , Ratos Sprague-Dawley , Receptores Acoplados a Proteínas G , Receptores de Neuropeptídeos/metabolismo , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Fatores de Virulência de Bordetella/farmacologia
6.
Peptides ; 22(11): 1803-7, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11754966

RESUMO

Adrenomedullin gene products have been localized to neurons in brain that innervate sites known to be important in the regulation of cardiovascular function. Those sites also have been demonstrated to possess receptors for the peptide and central administrations of adrenomedullin (AM) and proadrenomedullin N-terminal 20 peptide (PAMP) elevate blood pressure and heart rate in both conscious and anesthetized animals. The accumulated evidence points to a role of the sympathetic nervous system in these cardiovascular effects. These sympathostimulatory actions of AM and PAMP have been hypothesized to be cardioprotective in nature and to reflect the central nervous system (CNS) equivalent of the direct cardiostimulatory effects of the peptides in the periphery. This review summarizes the most recent data on the CNS actions of the adrenomedullin gene-derived peptides and suggests future strategies for the elucidation of the physiologic relevance of the already demonstrated, pharmacologic actions of these peptides.


Assuntos
Sistema Nervoso Autônomo/fisiologia , Fragmentos de Peptídeos/fisiologia , Peptídeos/fisiologia , Proteínas/fisiologia , Adrenomedulina , Animais , Sistema Cardiovascular/metabolismo , Sistema Nervoso Central/metabolismo , Humanos
7.
Brain Res ; 858(1): 19-25, 2000 Mar 06.
Artigo em Inglês | MEDLINE | ID: mdl-10700591

RESUMO

The physiological relevance of the recently described prolactin-releasing peptides (PrRPs) has yet to be established. Here, we demonstrate the low potency of the PrRPs (minimum effective dose: 100 nM), compared to that observed for thyrotropin-releasing hormone (TRH, minimum effective dose: 1.0 nM), to stimulate prolactin (PRL) release from cultured pituitary cells harvested from lactating female rats. Anatomic studies question the role of these peptides in neuroendocrine control of lactotroph function. Instead, peptide and peptide receptor mapping studies suggest potential actions in hypothalamus and brainstem unrelated to the control of anterior pituitary hormone secretion. Intracerebroventricular (i.c.v. ) administration of both PrRP-20 and PrRP-31 (0.4 and 4.0 nmol) resulted in significantly increased mean arterial blood pressure in conscious, unrestrained rats [peak elevations vs. baseline: PrRP-20, 10% and 16%, low and high dose peptide; PrRP-31, 7% and 10%; compared to the response to 0.1 nmol angiotensin II (A II), 15-17%]. Similar doses of peptide did not significantly alter water drinking in response to overnight fluid deprivation, or thirst or salt appetite in response to an isotonic hypovolemic challenge. Thus, the effect on blood pressure appeared relatively specific. We suggest that these peptides, identified originally as ligands for a receptor found in abundance in pituitary gland, play a broader role in brain function and that the ability of them to stimulate PRL release may not represent their primary biologic function.


Assuntos
Fenômenos Fisiológicos Cardiovasculares , Hormônios Hipotalâmicos/fisiologia , Neuropeptídeos/fisiologia , Angiotensina II/farmacologia , Animais , Pressão Sanguínea/efeitos dos fármacos , Fenômenos Fisiológicos Cardiovasculares/efeitos dos fármacos , Células Cultivadas , Relação Dose-Resposta a Droga , Comportamento de Ingestão de Líquido/efeitos dos fármacos , Feminino , Hormônios Hipotalâmicos/administração & dosagem , Injeções Intraventriculares , Lactação/metabolismo , Masculino , Neuropeptídeos/administração & dosagem , Adeno-Hipófise/citologia , Adeno-Hipófise/metabolismo , Prolactina/biossíntese , Hormônio Liberador de Prolactina , Ratos , Ratos Sprague-Dawley , Cloreto de Sódio na Dieta , Hormônio Liberador de Tireotropina/farmacologia , Privação de Água/fisiologia
8.
Annu Rev Physiol ; 61: 363-89, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10099693

RESUMO

Two potent hypotensive peptides, adrenomedullin (AM) and proadrenomedullin N-terminal 20 peptide (PAMP), are encoded by the adrenomedullin gene. AM stimulates nitric oxide production by endothelial cells, whereas PAMP acts presynaptically to inhibit adrenergic nerves that innervate blood vessels. Complementary, but mechanistically unique, actions also occur in the anterior pituitary gland where both peptides inhibit adrenocorticotropin release. In the adrenal gland both AM and PAMP inhibit potassium and angiotensin II-stimulated aldosterone secretion. Natriuretic and diuretic actions of AM reflect unique actions of the peptide on renal blood flow and tubular function. In the brain AM inhibits water intake and, in a physiologically relevant manner, salt appetite. Both AM and PAMP act in the brain to elevate sympathetic tone, effects that mirror the positive inotropic action of AM in the heart. Cardioprotective actions in the brain and heart may be important counter-regulatory actions that buffer the extreme hypotensive actions of the peptides when released in sepsis. Thus the biologic actions of the proadrenomedullin-derived peptides seem well coordinated to contribute to the physiologic regulation of volume and electrolyte homeostasis.


Assuntos
Líquidos Corporais/metabolismo , Eletrólitos/metabolismo , Homeostase/fisiologia , Peptídeos/fisiologia , Adrenomedulina , Animais , Humanos , Peptídeos/química , Peptídeos/genética , Processamento de Proteína Pós-Traducional , Transcrição Gênica/fisiologia
9.
Brain Res ; 818(1): 164-7, 1999 Feb 06.
Artigo em Inglês | MEDLINE | ID: mdl-9914451

RESUMO

Adrenomedullin (AM), a potent hypotensive peptide, is produced in numerous tissues including adrenal gland, kidney, brain and pituitary gland, where it acts to modify sodium homeostasis. Central AM administration dose-dependently inhibits sodium appetite. AM antisense oligonucleotide treatment significantly lowered peptide content in the hypothalamic paraventricular (PVN) nucleus and exaggerated the consumption of sodium. These results support a physiologic role for adrenomedullin gene products in the central regulation of sodium homeostasis.


Assuntos
Anti-Hipertensivos/farmacologia , Oligonucleotídeos Antissenso/farmacologia , Peptídeos/genética , Sódio/farmacologia , Adrenomedulina , Animais , Homeostase/efeitos dos fármacos , Masculino , Ratos , Ratos Sprague-Dawley
11.
Am J Physiol ; 274(5): R1505-9, 1998 05.
Artigo em Inglês | MEDLINE | ID: mdl-9612421

RESUMO

Peptides derived from postranslational processing of preproadrenomedullin exert potent hypotensive effects in the periphery. One of those peptides, adrenomedullin (AM) also has been demonstrated to act centrally in conscious rats to inhibit water drinking and salt appetite and, in anesthetized rats, surprisingly to increase blood pressure. We examined the effects of AM and the other postranslational product, proadrenomedullin NH2-terminal 20 peptide (PAMP), on blood pressure in conscious rats. Both AM and PAMP elicited dose-related increases in mean arterial pressure after cerebroventricular administration. The hypertensive effects of both AM and PAMP and of ANG II were blocked by peripheral administration of phentolamine, indicating actions of the peptides in brain to stimulate sympathetic nervous system function. Blockade of central ANG II receptors with saralasin prevented the hypertensive effects of both ANG II and PAMP, suggesting recruitment of endogenous angiotensinergic systems by central PAMP. The structural homolog of AM, calcitonin gene-related peptide (CGRP), at similar doses did nto significantly affect blood pressure. Furthermore, the hypertensive effects of ANG II, AM, and PAMP were not abrogated by prior administration of the CGRP antagonist. We hypothesize that AM and PAMP exert cardioprotective effects in brain, which may counterbalance the volume-unloading actions of the peptides in the periphery.


Assuntos
Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Cardiotônicos/farmacologia , Sistema Nervoso Central/fisiologia , Fragmentos de Peptídeos/farmacologia , Peptídeos/farmacologia , Proteínas/farmacologia , Vasodilatadores/farmacologia , Adrenomedulina , Animais , Masculino , Peptídeos/química , Ratos
12.
Front Neuroendocrinol ; 19(2): 100-27, 1998 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9578982

RESUMO

Posttranslational processing of the adrenomedullin gene product results in the formation of at least two biologically active peptides, adrenomedullin (AM) and proadrenomedullin N-20 terminal peptide (PAMP). Produced predominantly in the vasculature, both peptides are potent hypotensive agents, albeit via unique mechanisms of action. The gene is transcribed in a variety of other tissues including brain, pituitary, and kidney. Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, AM is diuretic and natriuretic, and both AM and PAMP inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion, again by apparently differing mechanisms. Additionally, AM antagonizes CRH-stimulated ACTH release. The peptides are produced in numerous brain sites, including hypothalamus and brainstem. Inhibition of AVP release has been reported and the physiologic significance of AM's ability to inhibit water drinking and salt appetite has been established. Thus the peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in the blood vessel. Interestingly, direct cardiac effects (positive inotropism and chronotropism) and CNS actions (sympathostimulation) have been reported, leading to the hypothesis that these peptides also can exert important cardioprotective effects, helping to prevent vascular collapse during states of high AM secretion such as sepsis.


Assuntos
Peptídeos/fisiologia , Precursores de Proteínas/fisiologia , Proteínas/fisiologia , Adrenomedulina , Animais , Fenômenos Fisiológicos Cardiovasculares , Homeostase , Humanos , Hipotálamo/fisiologia , Rim/fisiologia , Peptídeos/farmacologia , Hipófise/fisiologia , Precursores de Proteínas/farmacologia , Proteínas/farmacologia
13.
Endocrine ; 9(3): 269-72, 1998 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-10221592

RESUMO

Preproadrenomedullin is processed into at least two biologically active peptides, adrenomedullin (AM) and proadrenomedullin N-terminal 20 peptide (PAMP). Both peptides are hypotensive; however, they exert this action via differing mechanisms. In pituitary cells in culture, both basal and releasing factor-stimulated adrenocorticotropin (ACTH) secretion is inhibited by AM. Here we report that basal, but not stimulated, ACTH secretion from cultured rat pituitary cells is also inhibited by PAMP. The effect is dose-related, occurs in a physiologically relevant dose range that is similar to that of AM, and is blocked by the potassium channel blocker, glybenclamide. The failure of glybenclamide to inhibit AM's effects on ACTH secretion indicates that in pituitary, as in other tissues, these two products of the same prohormone can exert similar biologic activity, although via differing mechanisms.


Assuntos
Hormônio Adrenocorticotrópico/metabolismo , Fragmentos de Peptídeos/farmacologia , Peptídeos , Adeno-Hipófise/metabolismo , Canais de Potássio/metabolismo , Proteínas/farmacologia , Trifosfato de Adenosina/metabolismo , Adrenomedulina , Animais , Células Cultivadas , Glibureto/farmacologia , Hipoglicemiantes/farmacologia , Masculino , Adeno-Hipófise/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley
14.
Endocrine ; 9(3): 289-91, 1998 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-10221595

RESUMO

The prolactin- (PRL) releasing activities of the newly described PRL-releasing peptides (PrRPs) were compared to that of thyrotropin-releasing hormone (TRH) in dispersed, rat anterior pituitary cell cultures. A dose-related stimulation of PRL release by TRH was observed in cells harvested from both intact male and random cycle female pituitary donors. The minimum effective dose of TRH ranged from 1 to 10 nM. Neither PrRP-20 nor PrRP-31 significantly altered PRL secretion in cells from male donors even at doses as high as 1 microM. In cells harvested from females, only the highest doses of PrRP-20 and PrRP-31 tested (0.1 and 1.0 microM) significantly stimulated PRL secretion. The PRL-releasing action of TRH was observed already at 15 min of incubation, whereas those of PrRP-20 and PrRP-31 appeared only after 1 and 2 h of incubation, and the magnitude of PRL release in the presence of 1 microM PrRPs was significantly less than that of a similar dose of TRH. These data do not suggest a physiologically relevant role for the PrRPs in the neuroendocrine regulation of PRL secretion in intact male and nonlactating, random-cycle female rats.


Assuntos
Hormônios Hipotalâmicos/farmacologia , Neuropeptídeos/farmacologia , Adeno-Hipófise/efeitos dos fármacos , Caracteres Sexuais , Hormônio Liberador de Tireotropina/farmacologia , Animais , Células Cultivadas , Feminino , Masculino , Adeno-Hipófise/metabolismo , Prolactina/metabolismo , Hormônio Liberador de Prolactina , Ratos , Ratos Sprague-Dawley
15.
Endocrinology ; 138(2): 613-6, 1997 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-9002994

RESUMO

Adrenomedullin (AM) exerts profound natriuretic and vasodilatory effects in conscious animals. This newly discovered hormone also acts in the central nervous system to inhibit water drinking and in the pituitary gland to reduce basal and stimulated ACTH release. We investigated whether the natriuretic action of AM in kidney was matched by a central nervous system action to decrease salt intake. Isotonic hypovolemia induced in male rats by pretreatment with polyethylene glycol potently stimulates both water and salt water (0.3 mol/liter NaCl) drinking. Saline drinking was significantly inhibited when AM was administered into the lateral cerebroventricle before the drinking interval. The effect was dose related (dose range, 44-88 pmol), long lasting (> 5 h), and reversible (resolved at 24 h). When hypovolemic rats were administered antiserum to AM (intracerebroventricular administration) before the drinking interval, a significant 2-fold augmentation of saline drinking was observed. These data suggest that in addition to peripheral actions on cardiovascular and renal function and pituitary actions to inhibit ACTH release, AM may act within the central nervous system to determine fluid and electrolyte balance and, ultimately, blood pressure.


Assuntos
Apetite/efeitos dos fármacos , Peptídeos/farmacologia , Cloreto de Sódio na Dieta/administração & dosagem , Adrenomedulina , Animais , Ingestão de Líquidos , Imunização Passiva , Injeções Intraventriculares , Cinética , Masculino , Peptídeos/administração & dosagem , Peptídeos/imunologia , Ratos , Ratos Sprague-Dawley , Soluções
16.
Endocrinology ; 137(5): 1814-22, 1996 May.
Artigo em Inglês | MEDLINE | ID: mdl-8612519

RESUMO

Calcitonin (CT) inhibits secretion of PRL when administered intravenously in rats and humans. It also inhibits PRL release from cultured rat anterior pituitary (AP) cells. Recent evidence suggests that CT-like immunoreactive peptide is synthesized and released from the AP gland. However, its physiological role in the regulation of PRL secretion has not been understood. Present studies tested the role of endogenous pituitary CT (pit-CT) in the regulation of PRL secretion in vivo by passive immunization. In the first group of experiments, ovariectomized (ovx) adult female rats were administered either preimmune or anti-salmon CT (sCT) serum, and their serum PRL levels were analyzed at various time points up to 3 h. A second group of experiments examined the effects of anti-sCT serum and dopamine on PRL release from cultured rate AP cells. In the next group of experiments, the regional distribution of pit-CT secretion was examined in different sections of the AP gland. In the last set, CT-like activity of AP extract was tested in neonatal rat kidney cells, which respond to CT with an increase in cAMP accumulation. These experiments also tested whether anti-sCT serum reduces AP extract-induced increase in cAMP accumulation. The results suggest that anti-sCT serum dramatically increased serum PRL levels (by 5-fold) of ovx rats within 30 min of administration. The serum PRL levels declined gradually after the peak. However, a significant increase in serum PRL levels was maintained by the anti-sCT serum for the duration of the experiment. The anti-serum also induced a significant increase in PRL release from cultured AP cells when added to the presence or absence of dopamine. The distribution profile of pit-CT within the AP gland suggests that the release of pit-CT immunoreactivity was significantly greater in the inner sections, and anti-sCT serum also caused greater increase in PRL release in these sections. Finally, AP extract and sCT stimulated cAMP accumulation in neonatal rat kidney cells, and anti-sCT serum significantly reduced AP extract-induced cAMP accumulation. These results demonstrate that pit-CT is an important regulator of tonic PRL secretion in female rats and can potently inhibit PRL secretion even in the presence of dopamine.


Assuntos
Calcitonina/fisiologia , Ovariectomia , Prolactina/metabolismo , Animais , Animais Recém-Nascidos/metabolismo , Calcitonina/antagonistas & inibidores , Calcitonina/imunologia , Calcitonina/farmacologia , AMP Cíclico/metabolismo , Dopamina/farmacologia , Feminino , Imunização Passiva , Rim/efeitos dos fármacos , Rim/metabolismo , Adeno-Hipófise/metabolismo , Ratos
17.
Proc Soc Exp Biol Med ; 211(2): 178-83, 1996 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8599025

RESUMO

We investigated the effects of a constant infusion of adrenomedullin (ADM) on renal hemodynamics and fluid electrolyte excretion in the rat. Following baseline measurements, eight rats received an intravenous infusion of 5 micrograms of rat ADM (167 ng/min) for 30 min at 10 microliters/min. Eight additional rats received 0.9% saline at 10 microliters/min instead of ADM. Renal function was measured during this period and for two consecutive 20-min periods following termination of the ADM or vehicle infusion. Mean arterial pressure decreased from a baseline of 113 +/- 3 to 102 +/- 1 mm Hg at 25 min of ADM infusion and returned towards control after the ADM infusion was terminated. This modest hypotensive effect was associated with an increase in heart rate from 366 +/- 10 to 384 +/- 9 bpm, which continued to remain elevated after the ADM infusion was stopped. Urinary sodium excretion increased from 348 +/- 57 to 813 +/- 172 nEq/min during ADM infusion and continued to increase to 1141 +/- 347 nEq/min after the infusion of ADM was terminated. Urinary potassium excretion increased from 1.94 +/- 0.22 to 2.75 +/- 0.24 microEq/min during ADM infusion. Urine flow tended to increase (P = 0.08) from 7.0 +/- 0.5 to 8.1 +/- 0.6 microliters/min during ADM infusion and continued to increase to 9.7 +/- 1.5 microliters/min after the infusion was stopped. Renal plasma flow increased from 3.22 +/- 0.22 to 3.82 +/- 0.20 ml/min/g kidney wt during ADM infusion and continued to increase to 4.14 +/- 0.22 ml/min/g kidney wt after the ADM infusion was stopped. Glomerular filtration rate averaged to 1.11 +/- 0.07 ml/min/g kidney wt during baseline and did not significantly change during or after ADM infusion. These results indicate that a constant infusion of adrenomedullin, at a dose that results in a minimal hypotensive effect increases renal plasma flow and urinary sodium excretion in the rat.


Assuntos
Anti-Hipertensivos/farmacologia , Rim/efeitos dos fármacos , Peptídeos/farmacologia , Vasodilatadores/farmacologia , Adrenomedulina , Animais , Pressão Sanguínea/efeitos dos fármacos , Rim/fisiologia , Masculino , Natriurese/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley
18.
Endocrinology ; 136(6): 2459-63, 1995 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-7750467

RESUMO

The novel hormone, adrenomedullin (AdM), which exerts potent hypotensive effects in the periphery and natriuretic actions in the kidney, was found to be antidipsogenic. Cerebroventricular injection of AdM (22, 44, and 88 pmol) resulted in a dose-related diminution of water drinking in response to subsequent central administration of 100 pmol angiotensin II. Additionally, 88 pmol AdM significantly inhibited the drinking response to overnight water deprivation and hyperosmotic challenge. No significant effects of AdM in the doses tested were observed on blood pressure, heart rate, or motor activity. These results suggest that this novel hormone can act within the nervous system to complement its peripheral actions on fluid and electrolyte homeostasis, independent of a central action on cardiovascular function or locomotion.


Assuntos
Anti-Hipertensivos/farmacologia , Ingestão de Líquidos/efeitos dos fármacos , Peptídeos/farmacologia , Adrenomedulina , Animais , Anti-Hipertensivos/administração & dosagem , Pressão Sanguínea/efeitos dos fármacos , Relação Dose-Resposta a Droga , Ingestão de Líquidos/fisiologia , Frequência Cardíaca/efeitos dos fármacos , Injeções Intraventriculares , Masculino , Peptídeos/administração & dosagem , Ratos , Ratos Sprague-Dawley , Solução Salina Hipertônica/administração & dosagem , Privação de Água/fisiologia , Equilíbrio Hidroeletrolítico/efeitos dos fármacos
19.
Endocrinology ; 136(5): 2349-52, 1995 May.
Artigo em Inglês | MEDLINE | ID: mdl-7720684

RESUMO

The potent hypotensive peptide, adrenomedullin (AdM), originally isolated from a human pheochromocytoma is present in a variety of rat and human tissues. We examined its potential effects in anterior pituitary gland, reasoning that it may be a feedback regulator of adrenocorticotropin (ACTH) secretion. Rat AdM11-50 inhibited basal ACTH secretion from dispersed, rat anterior pituitary cells in a significant, dose-related fashion (maximum inhibition at 10(-9) M). Rat AdM11-50 also inhibited, in a dose-related fashion, corticotropin releasing hormone (CRH)-stimulated ACTH secretion, but did not block the ability of CRH to stimulate cAMP accumulation in these cells. These findings suggest that in addition to peripheral actions in the vasculature and kidney, adrenomedullin may act within the anterior pituitary gland to control fluid and electrolyte homeostasis.


Assuntos
Hormônio Adrenocorticotrópico/metabolismo , Anti-Hipertensivos/farmacologia , Hormônio Liberador da Corticotropina/farmacologia , Peptídeos/farmacologia , Adeno-Hipófise/metabolismo , Hormônio Adrenocorticotrópico/antagonistas & inibidores , Adrenomedulina , Animais , Células Cultivadas , AMP Cíclico/metabolismo , Relação Dose-Resposta a Droga , Cinética , Masculino , Adeno-Hipófise/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley
20.
Adv Exp Med Biol ; 395: 355-64, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-8713991

RESUMO

Release of oxytocin into the vicinity of the long portal vessels connecting the hypothalamus with the anterior pituitary gland and the presence of short portal vessels connecting the posterior lobe to the anterior pituitary established the potential for the peptide to act in a neuroendocrine fashion controlling the release of one or several adenohypophyseal hormones. Indeed, oxytocin receptors are present in the gland and numerous trophic effects of the peptide have been described, some with apparent physiological relevance. Thus under defined physiologic conditions a participatory role for oxytocin in the physiologic regulation of at least two hormones, prolactin and adrenocorticotropin, has been evidenced and there is developing credence to the concept that oxytocin may indirectly control gonadotroph function as well. Most recently, novel technologies have identified subpopulations of oxytocin receptive cells within a given cell type in the anterior pituitary gland and the concept of a modulatory effect of the nonapeptide on primary regulatory events has arisen.


Assuntos
Ocitocina/fisiologia , Adeno-Hipófise/fisiologia , Hormônio Adrenocorticotrópico/metabolismo , Animais , Feminino , Gonadotropinas Hipofisárias/metabolismo , Humanos , Hormônio Luteinizante/metabolismo , Prolactina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA